KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Other Working Capital Changes (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 17 years of Other Working Capital Changes data on record, last reported at -$509.8 million in Q4 2025.

  • For Q4 2025, Other Working Capital Changes fell 1021.88% year-over-year to -$509.8 million; the TTM value through Dec 2025 reached -$51.7 million, down 112.69%, while the annual FY2025 figure was -$51.7 million, 112.69% down from the prior year.
  • Other Working Capital Changes reached -$509.8 million in Q4 2025 per REGN's latest filing, down from $47.9 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $487.3 million in Q2 2024 and bottomed at -$509.8 million in Q4 2025.
  • Average Other Working Capital Changes over 5 years is $23.5 million, with a median of $43.0 million recorded in 2023.
  • The widest YoY moves for Other Working Capital Changes: up 14232.35% in 2024, down 1700.0% in 2024.
  • A 5-year view of Other Working Capital Changes shows it stood at -$143.6 million in 2021, then soared by 139.42% to $56.6 million in 2022, then dropped by 24.03% to $43.0 million in 2023, then rose by 28.6% to $55.3 million in 2024, then plummeted by 1021.88% to -$509.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Working Capital Changes were -$509.8 million in Q4 2025, $47.9 million in Q3 2025, and $230.7 million in Q2 2025.